Table 7. Univariable and multivariable predictors of major bleedings.
| Unadjusted HR (95%CI) | P value | Adjusted* HR (95% CI) |
P value | |
|---|---|---|---|---|
| Age (years), mean (SD) | 1.02 (0.98–1.06) | 0.303 | - | - |
| Age ≥ 75 y | 2.41 (0.98–5.93) | 0.056 | 1.36 (0.44–4.24) | 0.597 |
| Gender, males | 0.97 (0.35–2.69) | 0.954 | - | - |
| BMI ≥ 30 Kg/m2 | 0.47 (0.11–2.03) | 0.310 | - | - |
| LVEF<40% | 3.61 (1.42–9.18) | 0.007 | 2.71(0.90–8.20) | 0.078 |
| Hypertension | 0.80 (0.30–2.10) | 0.646 | - | - |
| Hypercholesterolemia | 0.99 (0.41–2.46) | 0.999 | - | - |
| Smoking habit | 0.72 (0.29–1.78) | 0.469 | - | - |
| Diabetes | 1.02 (0.37–2.83) | 0.971 | - | - |
| Family history for CAD | 0.62 (0.21–1.86) | 0.391 | - | - |
| Previous Myocardial infarction | 0.23 (0.03–1.71) | 0.151 | - | - |
| Previous PCI, n (%) | 0.48 (0.11–2.08) | 0.328 | - | - |
| Non Valvular Atrial Fibrillation | 3.80 (1.35–10.72) | 0.011 | 2.89 (0.56–14.84) | 0.203 |
| Valvular Atrial Fibrillation | 12.92 (2.98–56.0) | 0.001 | 7.04 (0.69–71.63) | 0.099 |
| Peripheral Artery Disease | 0.77 (0.10–5.82) | 0.805 | - | - |
| Chronic Kidney Disease | 1.21 (0.16–9.08) | 0.852 | - | - |
| Cerebrovascular disease | 1.74 (0.23–13.07) | 0.591 | - | - |
| Previous Major Bleeding | 3.19 (0.43–23.91) | 0.259 | - | - |
| Unstable Angina | 1 | - | - | - |
| NSTEMI | 0.79 (0.20–3.20) | 0.789 | - | - |
| STEMI | 0.89 (0.24–3.25) | 0.886 | - | - |
| Proton Pump Inhibitors | 0.50 (0.07–3.80) | 0.505 | - | - |
| Statins | 0.65 (0.09–4.85) | 0.671 | - | - |
| Beta-Blockers | 0.57 (0.23–1.42) | 0.229 | - | - |
| Diuretics | 2.82 (1.14–7.00) | 0.025 | 1.70 (0.58–5.00) | 0.333 |
| ACE inhibitors/ARBS | 0.58 (0.24–1.42) | 0.232 | - | - |
| Nitrates | 0.99 (0.23–4.36) | 0.995 | - | - |
| Vitamin K Antagonists | 2.95 (0.96–9.05) | 0.059 | 0.51 (0.08–3.15) | 0.472 |
| Antiplatelet Therapies | ||||
| Aspirin+Clopidogrel | 1 | |||
| Aspirin+Prasugrel | 0.63 (0.13–3.02) | 0.562 | 2.16 (0.36–12.99) | 0.400 |
| Aspirin+Ticagrelor | 0.64 (0.22–1.82) | 0.402 | 1.44 (0.42–4.95) | 0.558 |
| Duration of Antiplatelet Therapies (days) | 0.994 (0.991–0.997) | <0.001 | - | - |
| Duration of Antiplatelet Therapies (for each SD increase) | 0.45 (0.31–0.65) | 0.001 | 0.39 (0.24–0.65) | <0.001 |